AstraZeneca PLCAZN:LSE

4,175
132.50 / 3.28%
5.27m
23.16%
0.3384
Close in GBXToday's changeShares traded1 year changeBeta
As of Apr 24 2014 17:14 BST.Data delayed by at least 15 minutes.

Summary

AstraZeneca PLC (AZN:LSE) set a new 52-week high during today's trading session when it reached 4,296.5. Over this period, the share price is up 25.55%.

52-week range
Today
3,028.5
Jun 25 2013
4,296.5
Apr 24 2014
Open4,010
Day high4,296.5
Day low4,008.5
Bid4,060
Offer4,200
Previous close4,042.5
Average volume4.13m
Shares outstanding1.26bn
Free float1.26bn
P/E (TTM)33.32
Market cap51.12bn GBP
EPS (TTM)1.22 GBP
Annual div (TTM)176.33 GBX
Annual div yield (TTM)4.36%
Div ex-dateFeb 19 2014
Div pay-dateMar 24 2014
Last IC View
The last IC recommendation on AstraZeneca PLC shares was Buy at 4,032 on 23 Apr 2014
Read the full article

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
AstraZeneca PLC+10.41%+7.99%+29.46%+23.16%+74.39%
FTSE 100 Index+1.17%+2.80%-0.15%+4.22%+61.29%
GB/HEALTH CARE+7.31%+4.89%+11.42%+10.54%--
GB/PHARMACEUTICALS+7.45%+5.16%+11.40%+10.15%--
As of Apr 24 2014 17:14 BST.Data delayed by at least 15 minutes.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.